Unlocking the true clinical potential of
cannabinoid-based medicines

cannaflos-icon-from_plant-v1

Plant based
therapeutics


We develop APIs from IP-protected genetics, to amplify and harness the therapeutic power of the cannabis plant.

cannaflos-icon-to_therapy-v1

Pharmaceutical
rigor


We are experts in pharmaceutical development on the endocannabinoid system, conducting tailored pre- and clinical trials.

cannaflos-icon-to_market-v1

Regulatory
excellence


We enable a secure and fast-track to market through in-depth expertise on and adherence to the requirements of European and national regulatory authorities (EMA/BfArM) while ensuring EU GxP compliant supply chains.

cannaflos-icon-to_patient-v1

Value through
collaboration


We are part of an excellent biopharma ecosystem of industry leaders, leading scientists and institutional players to create synergies and work efficiently.

We are Cannaflos, a European biopharmaceutical company
specialized in the endocannabinoid system, conducting clinical stage drug development from plant to patient.

Since 2019, we serve the medical cannabis industry with registered cannabis genetics and expertise in cultivation, production, clinical research, compliance and regulatory affairs.

Clinical-stage drug developement

We envision a future where Cannabinoid-based-medicine (CBM) is fully recognized, validated, and integrated into modern healthcare.

Therefore, we are on a mission to address critical unmet medical needs in neurology, through clinical stage development of cannabinoid-based medicines from plant to patient.

Genetics as the foundational IP for drug development

We have developed 19 highly therapeutic, EU-CPVO registered cannabis cultivars that serve as the starting material for API development to enter clinical trails. This approach lays the foundation for IP protection, batch-to-batch consistency and optimized therapeutic potential.

cannaflos-placeholder

We are research-driven

At Cannaflos, we believe good science means good business. Therefore, we pursue an evidence based approach across all our business endeavours.

To do so, our in-house scientists work hand in hand with top-tier academic and clinical researchers around the world to advance our knowledge for the benefit of the plant, the patient and the planet.

Shaping the future of medical Cannabis, together

Cannaflos works closely with international partners in cultivation, manufacturing, research and development, and regulatory affairs. We see a special potential in European cooperation.

We serve your needs across the Cannabis value chain

Our end-to-end capabilities

Leveraging business as a force for good

Planet

For us, being economically successful includes living and working in a way that conserves natural resources. Therefore, we seek fair and sustainable solutions and are committed to revenue sharing according to the Nagoya protocol for biodiversity and preservation.

Plant

We live up to our responsibility to protect the diversity of the Cannabis plant. Together with our partners, we leverage science to explore the enormous potential of the cannabis plant, while respecting its origins, cultural relevance and ecosystems.

People

Promoting quality of life lies at the core of what we do. We are committed to leveraging medical Cannabis as a means to improve the quality of life of our patients, physicians and pharmacists. In the process, we ensure the well being and benefit of employees and partners.

Profit

We build a transparent, responsible and sustainable relation with our shareholders, cultivated through a mutual understanding and commitment to our triple bottom line approach. We aiming to maximize shareholder value while ensuring ethical decision-making.


Jonathan Haehn

CEO & Co-Founder Cannaflos GmbH

cannaflos-icon-quotation-mark-v2

Compliance is key to success for the Cannabis industry. We take this seriously as we passionately drive research into new genetics for reliable drug development and supporting diversity in cannabis.